Maxacalcitol
- Generic Name
- Maxacalcitol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H42O4
- CAS Number
- 103909-75-7
- Unique Ingredient Identifier
- N2UJM5NBF6
- Associated Conditions
- -
- Associated Therapies
- -
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-04-26
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 255
- Registration Number
- NCT01341782
- Locations
- 🇯🇵
Site Reference ID/Investigator# 53485, Aichi, Japan
🇯🇵Site Reference ID/Investigator# 54387, Sakai, Japan
🇯🇵Site Reference ID/Investigator# 52748, Osaka, Japan
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Abbott
- Target Recruit Count
- 47
- Registration Number
- NCT00990704
- Locations
- 🇯🇵
Site Ref # / Investigator 53789, Tokyo, Japan
🇯🇵Site Ref # / Investigator 53793, Toyohashi, Japan
🇯🇵Site Ref # / Investigator 53788, Yachiyo, Japan
Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Abbott
- Target Recruit Count
- 153
- Registration Number
- NCT00667576
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath